Neoss Inc. Unveils New NeoGenix™ Extraction Allograft

Neoss Inc., a prominent player in dental implant technology, has announced the release of its latest biomaterial innovation, the NeoGenix™ Extraction Allograft. This new product, made from 100% human allograft bone, has been engineered to support dental practitioners in enhancing patient outcomes with a streamlined approach to bone regeneration. Neoss introduced the NeoGenix Extraction Allograft with the goal of offering a simplified, single-step solution designed to meet the needs of a broad range of dental professionals.

Advanced Composition for Enhanced Bone Growth

The NeoGenix Extraction Allograft is crafted from a precise combination of demineralized bone fibers and mineralized bone particles, integrating both cortical and cancellous bone materials. This unique blend forms a plug-shaped allograft that optimizes the environment for bone regeneration, promoting quicker and stronger bone growth. Designed to eliminate additional steps often required in bone grafting—such as mixing particulate grafts or applying a separate membrane—the allograft simplifies the procedure, making it more efficient for clinicians.

John Chopack, Managing Director of Neoss USA, highlighted the product’s potential, saying, “We’re pleased to offer a new allograft fiber for extraction sites that not only delivers cost-effective results but also fosters faster, stronger bone growth.” Chopack further noted that the NeoGenix Extraction Allograft helps maintain the bone structure, ensuring that future implant options remain open for patients. This feature underscores the product’s suitability for practitioners seeking reliable, long-term solutions for their patients’ dental health.

Cost-Effective and Predictable Alternative to Traditional Grafts

Positioned as an affordable alternative to traditional xenografts and synthetic options, the NeoGenix Extraction Allograft is intended to provide predictable results that improve the overall quality of patient care. Neoss aims to support dental professionals by reducing complexity without compromising clinical effectiveness. The allograft’s one-step application method provides a time-saving advantage for clinicians, aligning with Neoss’s ethos of “Intelligent Simplicity.”

The NeoGenix Extraction Allograft promises consistent outcomes that make it a trusted choice in the dental implant industry, offering both ease of use and clinical dependability. Its focus on patient-friendly innovation reflects Neoss’s commitment to setting new standards in the dental implant market, particularly through products that cater to both practitioner needs and patient outcomes.

About Neoss Inc.

Founded on principles of ingenuity and simplicity, Neoss Inc. designs dental products that are accessible and effective for practitioners worldwide. Headquartered in Harrogate, UK, with research and development facilities in Gothenburg, Sweden, Neoss has established a global presence, continually aiming to make complex dental procedures more approachable. The company’s mission is to enable dental professionals to provide high-quality, cost-effective care while ensuring durable, positive results for patients.